Clinical TrialsEPIX announced the discontinuation of masofaniten's randomized Phase II trial in combination with enzalutamide in anti-androgen naive mCPRC following an interim analysis that suggested the trial was unlikely to meet the primary endpoint.

Drug DevelopmentEPIX announced that it will discontinue all masofaniten development following a pre-specified futility analysis that showed that this candidate failed to meet the target efficacy profile in the Phase 2 enzalutamide combo study in mCRPC patients naïve to second-generation antiandrogens.

ESSA Pharma News

XenoTherapeutics to acquire Essa Pharma

ESSA Pharma (EPIX) announced that it has entered into a definitive agreement with XenoTherapeutics under which Xeno will...

22d ago

EPIX

XOMA

ESSA Pharma Announces Tax Implications of Cash Distribution

ESSA Pharma ( ($EPIX) ) has shared an update. On July 31, 2025, ESSA Pharma Inc. informed its...

4d ago

EPIX

ESSA Pharma Seeks Court Approval for Cash Distribution Amid XenoTherapeutics Merger

ESSA Pharma ( ($EPIX) ) has issued an announcement. ESSA Pharma Inc. announced its intention to apply to...

13d ago

EPI

EPIX

ESSA Pharma to be Acquired by XenoTherapeutics in All-Cash Deal

ESSA Pharma ( ($EPIX) ) has provided an announcement. ESSA Pharma Inc. has entered into a definitive agreement...

13d ago

EPI

EPIX

ESSA Pharma to be Acquired by XenoTherapeutics

ESSA Pharma ( ($EPIX) ) just unveiled an announcement. On July 13, 2025, ESSA Pharma Inc. announced a...

22d ago

EPIX

ESSA Pharma Inc. Explores Strategic Alternatives After Clinical Trial Termination

ESSA Pharma Inc. ( ($EPIX) ) has released its Q2 earnings. Here is a breakdown of the information...

3M ago

EPIX

ESSA Pharma Reports Q2 2025 Financial Results and Strategic Review

ESSA Pharma ( ($EPIX) ) has issued an announcement. ESSA Pharma Inc. reported a net loss of $6.4...

3M ago

EPI

EPIX

EPIX Lawsuit Alert! Class Action Lawsuit Against ESSA Pharma, Inc.

A class action lawsuit was filed against ESSA Pharma, Inc. ($EPIX) by Levi & Korsinsky on January 24, 2025. The...

5M ago

EPIX

ESSA Pharma Inc. Explores Strategic Options Amid Losses

ESSA Pharma Inc. ( ($EPIX) ) has released its Q1 earnings. Here is a breakdown of the information...

6M ago

EPIX

ESSA Pharma Reports Q1 Loss, Explores Strategic Options

ESSA Pharma ( ($EPIX) ) just unveiled an update. ESSA Pharma has reported a net loss of $8.5...

6M ago

EPI

EPIX

Essa Pharma reports Q4 EPS (19c) vs. (14c) last year

As of December 31, 2024, the company had available cash reserves and short-term investments of $120.6M and net...

6M ago

EPIX

ESSA Pharma Inc. (EPIX) Q1 Earnings Cheat Sheet

ESSA Pharma Inc. (EPIX) is scheduled to report 1st quarter earnings on 02/06/2025. Regarding Q1 estimates, Wall Street...

6M ago

EPIX

Essa Pharma reports Q4 EPS (14c), consensus (27c)

As of September 30, the company had available cash reserves and short-term investments of $126.8M and net working...

8M ago

EPIX

Biotech Alert: Searches spiking for these stocks today

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by...

9M ago

NVO

VIR

EPIX FAQ

What was ESSA Pharma Inc.’s price range in the past 12 months?

ESSA Pharma Inc. lowest stock price was $1.40 and its highest was $7.88 in the past 12 months.

What is ESSA Pharma Inc.’s market cap?

ESSA Pharma Inc.’s market cap is $83.45M.

When is ESSA Pharma Inc.’s upcoming earnings report date?

ESSA Pharma Inc.’s upcoming earnings report date is Aug 06, 2025 which is tomorrow.

How were ESSA Pharma Inc.’s earnings last quarter?

ESSA Pharma Inc. released its earnings results on May 08, 2025. The company reported -$0.14 earnings per share for the quarter, beating the consensus estimate of -$0.19 by $0.05.

Is ESSA Pharma Inc. overvalued?

According to Wall Street analysts ESSA Pharma Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does ESSA Pharma Inc. pay dividends?

ESSA Pharma Inc. does not currently pay dividends.

What is ESSA Pharma Inc.’s EPS estimate?

ESSA Pharma Inc.’s EPS estimate is -0.17.

How many shares outstanding does ESSA Pharma Inc. have?

ESSA Pharma Inc. has 44,388,550 shares outstanding.

What happened to ESSA Pharma Inc.’s price movement after its last earnings report?

ESSA Pharma Inc. reported an EPS of -$0.14 in its last earnings report, beating expectations of -$0.19. Following the earnings report the stock price went down -1.156%.

Which hedge fund is a major shareholder of ESSA Pharma Inc.?

Currently, no hedge funds are holding shares in EPIX

ESSA Pharma Stock Smart Score

Underperform

Fundamentals

Return on Equity

-23.07%

Trailing 12-Months

Asset Growth

-16.30%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

ESSA Pharma Inc.

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.